metaEvidence - overview


			deaths (OS)
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	atezolizumab alone vs. gemcitabine plus platin	1	1.02 [0.83; 1.25], 1 RCT, I2=0% inconclusive result
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	1	0.85 [0.73; 0.99], 1 RCT, I2=0% unassessable degree of certainty
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	0.87 [0.72; 1.06], 1 RCT, I2=0% inconclusive result
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus no additional treatment
	atezolizumab alone vs. no additional treatment	1	-
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive